ArticleCureus2025
Prognostic Significance of Left Atrial Size in the Recurrence of Atrial Fibrillation.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAtrial fibrillation (AF) is associated with significant morbidity and recurrence despite rhythm control strategies. Identifying reliable predictors of AF recurrence is essential for optimizing patient management.
aimThe aim of this study was to evaluate the predictive value of left atrial (LA) diameter for AF recurrence at six and 12 months following rhythm control interventions.
methodsThis prospective observational study included 66 patients with documented AF who underwent rhythm control interventions, including electrical or pharmacological cardioversion. LA diameter was measured by transthoracic echocardiography in the parasternal long-axis view at end-systole, using a standardized protocol by a single blinded operator. LA volume and indexed measurements were not consistently available and were excluded. The primary endpoint was AF recurrence at six and 12 months. AF recurrence was defined as any documented AF episode lasting >30 seconds, confirmed by 12-lead ECG during scheduled visits or symptom-driven ECG recordings. Follow-up was conducted at six and 12 months. Two patients were lost to follow-up.
resultsThe study included 66 patients (71.2% men) with a mean age of 65.4 ± 13.7 years. Hypertension (74.2%) and dyslipidemia (54.5%) were the most prevalent comorbidities, while 28.8% were smokers. Mean left ventricular ejection fraction was 52.3 ± 10.5%, with 77.3% of patients having preserved systolic function (LVEF ≥ 50%). Mean left atrial diameter was 43.5 ± 7.2 mm; 31.8% had LA diameter <40 mm, and 12.1% >50 mm. Rhythm control was achieved using electrical cardioversion or antiarrhythmic drugs, with palpitations being the most common presenting symptom. AF recurrence occurred in 51.6% of patients at six months and 50.8% at 12 months. Background pharmacotherapy remained stable during follow-up. LA size >42.5 was significantly associated with having an AF episode at six (OR=7.55; 95%CI: 2.22 - 25.66; p=0.001) and 12 months (OR=41.97; 95%CI: 7.37 - 239.07; p<0.001), after adjusting simultaneously for age, gender, smoking, alcohol, and number of comorbidities. Also, patients who smoked had a significantly greater probability of having an AF episode at 12 months (OR=12.9; 95%CI: 1.70 - 97.75; p=0.001). All possible interactions were tested, but no significant results emerged. The change in AF type distribution (from paroxysmal to persistent) between consecutive timepoints was not significant (p>0.05).
conclusionsLA diameter >42.5 mm is a simple, non-invasive, and powerful predictor of AF recurrence after rhythm control. Its routine assessment may enhance early risk stratification and guide individualized therapeutic strategies in patients with AF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.